AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.13 |
Market Cap | 234.27M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.31 |
PE Ratio (ttm) | -7.32 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3 |
Volume | 334,106 |
Avg. Volume (20D) | 1,626,654 |
Open | 2.30 |
Previous Close | 2.27 |
Day's Range | 2.19 - 2.34 |
52-Week Range | 1.61 - 4.62 |
Beta | undefined |
About PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in...
Analyst Forecast
According to 5 analyst ratings, the average rating for PRQR stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 252.42% from the latest price.
Next Earnings Release
Analysts project revenue of $6.97M, reflecting a 97.17% YoY growth and earnings per share of -0.15, making a 87.50% increase YoY.